Drugging KRAS: a Once ‘Undruggable’ Target

<!doctype html><html lang="en"><head> <meta charset="utf-8"> <title>Drugging KRAS: a Once ‘Undruggable’ Target</title> <link rel="shortcut icon" href="https://oxfordglobal.com/hubfs/OXFORD_GLOBAL-LOGO_SYMBOL.jpg"> <meta name="description" content="RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’"> <meta name="viewport" content="width=device-width, initial-scale=1"> <meta property="og:description" content="RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’"> <meta property="og:title" content="Drugging KRAS: a Once ‘Undruggable’ Target"> <meta name="twitter:description" content="RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’"> <meta name="twitter:title" content="Drugging KRAS: a Once ‘Undruggable’ Target"> <style> a.cta_button{-moz-box-sizing:content-box !important;-webkit-box-sizing:content-box !important;box-sizing:content-box !important;vertical-align:middle}.hs-breadcrumb-menu{list-style-type:none;margin:0px 0px 0px 0px;padding:0px 0px 0px 0px}.hs-breadcrumb-menu-item{float:left;padding:10px 0px 10px 10px}.hs-breadcrumb-menu-divider:before{content:'›';padding-left:10px}.hs-featured-image-link{border:0}.hs-featured-image{float:right;margin:0 0 20px 20px;max-width:50%}@media (max-width: 568px){.hs-featured-image{float:none;margin:0;width:100%;max-width:100%}}.hs-screen-reader-text{clip:rect(1px, 1px, 1px, 1px);height:1px;overflow:hidden;position:absolute !important;width:1px} </style> <link rel="stylesheet" href="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135726131582/1732113079147/git/og-stage/css/main.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/fontawesome.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/brands.min.css"> <link rel="stylesheet" href="https://cdn.oxfordglobal.com/fontawesome/6.5.1/css/solid.min.css">  <style id="hs_editor_style" type="text/css"> #hs_cos_wrapper_module_17019620504109 { display: block !important; margin-bottom: 0px !important } </style>  <script> var _hsp = window._hsp = window._hsp || []; window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} var useGoogleConsentModeV2 = true; var waitForUpdateMillis = 1000; if (!window._hsGoogleConsentRunOnce) { window._hsGoogleConsentRunOnce = true; gtag('consent', 'default', { 'ad_storage': 'denied', 'analytics_storage': 'denied', 'ad_user_data': 'denied', 'ad_personalization': 'denied', 'wait_for_update': waitForUpdateMillis }); if (useGoogleConsentModeV2) { _hsp.push(['useGoogleConsentModeV2']) } else { _hsp.push(['addPrivacyConsentListener', function(consent){ var hasAnalyticsConsent = consent && (consent.allowed || (consent.categories && consent.categories.analytics)); var hasAdsConsent = consent && (consent.allowed || (consent.categories && consent.categories.advertisement)); gtag('consent', 'update', { 'ad_storage': hasAdsConsent ? 'granted' : 'denied', 'analytics_storage': hasAnalyticsConsent ? 'granted' : 'denied', 'ad_user_data': hasAdsConsent ? 'granted' : 'denied', 'ad_personalization': hasAdsConsent ? 'granted' : 'denied' }); }]); } } gtag('js', new Date()); gtag('set', 'developer_id.dZTQ1Zm', true); gtag('config', 'G-43QK8SYTST'); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-43QK8SYTST"></script>  <link rel="canonical" href="https://oxfordglobal.com/discovery-development/resources/drugging-kras-a-once-undruggable-target"> <meta property="og:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/6GJ8.png"> <meta name="twitter:image" content="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/6GJ8.png"> <meta property="og:url" content="https://oxfordglobal.com/discovery-development/resources/drugging-kras-a-once-undruggable-target"> <meta name="twitter:card" content="summary"> <meta http-equiv="content-language" content="en"> <meta name="generator" content="HubSpot"></head> <body class="discovery-development"> <div class="body-wrapper hs-content-id-177028096592 hs-site-page page "> <div data-global-resource-path="git/og-stage/templates/partials/header.html"> <header class="website-header "> <div class="navbar"> <div class="navbar-brands"> <a href="/discovery-development" class="logo-link current-brand"> <img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"> <i class="dropdown fa-solid fa-chevron-down"></i> </a> <div class="brands"> <div class="intro"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> </div> <div class="items"> <div class="item primary-brand"> <a href="/" class="logo-link"><img src="https://oxfordglobal.com/hubfs/logo.jpg" class="logo-image"></a> </div> <div class="item"> <a href="/precision-medicine" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Precision%20Medicine.svg" class="logo-image"></a> </div> <div class="item active-item"> <a href="/discovery-development" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/Discovery%20%26%20Development.svg" class="logo-image"></a> </div> <div class="item"> <a href="/nextgen-biomed" class="logo-link"><img src="https://oxfordglobal.com/hubfs/Website/Logos/Brand%20Logos/NextGen%20Biomed.svg" class="logo-image"></a> </div> </div> </div> </div> <div class="flex flex-align-center navbar-nav"> <a href="#" class="navbar-nav-toggle"> <div class="toggle-icons"> <i class="fa-solid fa-bars toggle-open"></i> <i class="fa-solid fa-xmark toggle-close"></i> </div> </a> <ul class="navbar-nav-items"> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Events <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Events.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-3 divider g-20"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person & Online Events </h3> <p>Pivotal moments where high-level industry experts and thought leaders come together for focused knowledge sharing and unparalleled networking opportunities.</p> </div> <div class="subnav-item"> <div class="event-pills"> <a href="/discovery-development/events/discovery-development-europe-2025" class="pill center"> <div class="b">Discovery & Development Europe 2025</div> <div class="heading-smallcaps"> 01 - 02 Jul 2025 | Basel, Switzerland </div> </a> <a href="/discovery-development/events/discovery-development-us-2025" class="pill center"> <div class="b">Discovery & Development US 2025</div> <div class="heading-smallcaps"> 02 - 03 Oct 2025 | San Diego, CA </div> </a> </div> </div> </div> <div class="subnav-item flex-2"> <div class="subnav-item-content bottom-mp-fix"> <h3> Online Activities </h3> <p>Our Monthly Science Exchanges and Webinars keep you connected to the conversation.</p> </div> <div class="online-activities-list flex flex-column g-10">  <div class="online-activity"> <a href="/discovery-development/online#Controlled%20Release%20Formulations" class="cta" target="_blank"> <h3 class="other-resources">26/06/24 - Controlled Release Formulations</h3> </a> </div> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/online" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Online Activities</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Community <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Community.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> About </h3> <p>We empower scientific decision-makers from the world’s most innovative biopharma organisations to make informed pipeline decisions in early R&D, accelerating their route from target ID to novel clinical candidate.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/about" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Community </h3> <p>Our community extends across the entire early R&D ecosystem, including biopharma, solution providers, start-ups, academics, and investors.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/community" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1 "> <div class="subnav-item-content bottom-mp-fix"> <h3> Media Partners </h3> <p>We work with leading journal publications on reciprocal marketing arrangements.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/media-partners" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Services <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Services.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex flex-1 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> In-Person Services </h3> <p>At Oxford Global, our events are designed to connect key life science figures and innovative solution providers, accelerating scientific advancement. Our goal is to create valuable connections and an impactful experience through innovative and collaborative formats.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/in-person-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> <div class="subnav-item flex flex-1"> <div class="subnav-item-content bottom-mp-fix"> <h3> Digital Marketing Services </h3> <p>Oxford Global’s products offer a powerful channel to associate your brand with the latest advancements within the industry whilst educating and influencing the industry throughout their buying process.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/digital-marketing-services" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> More Info</a> </div> </div> </div> </div> </li> <li class="navbar-nav-item"> <a href="#" class="navbar-nav-item-link">Resources <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-graphics"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Header%20Resources.jpg" class="subnav-image"> </div> <div class="subnav-items"> <div class="subnav-item flex-2 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Browse All Resources </h3> <p>Scientific & technical insights on the latest targets, platforms and processes impacting drug discovery & development.</p> </div> <div class="subnav-item-content-more"> <a href="/discovery-development/resources" class="subnav-item-content-more-link"><i class="fa-solid fa-circle-chevron-right"></i> All Discovery & Development Resources</a> </div> </div> <div class="subnav-item flex-4 divider"> <div class="subnav-item-content bottom-mp-fix"> <h3> Latest Resources </h3> <div class="resources"> <div class="resource"> <div class="resource-cover"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai" class="resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery%20and%20Development/BiomedGPT%20Adopting%20a%20Generalist%20Approach%20to%20Biomedical%20AI%20.png" class="resource-cover-image"> </a> </div> <div class="resource-content"> <h3 class="resource-heading"> <a href="/discovery-development/resources/biomedgpt-adopting-a-generalist-approach-to-biomedical-ai">BiomedGPT: Adopting a Generalist Approach to Biomedical AI </a> </h3> <div class="resource-abstract"> <span class="resource-date">11/11/24 - </span> BiomedGPT, a versatile AI tool used for biomedical research demonstrated impressive results across a wide range of healthcare tasks. </div> </div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment">07/11/24 - The Application of RNAi Therapeutics for Cardiovascular Disease Treatment</a></div> </div> <div class="top-divider"></div> <div class="resource"> <div class="other-resources"><a href="/discovery-development/resources/ai-ml-advancements-in-drug-formulation-the-potential-of-self-driving-labs">16/10/24 - AI/ML Advancements in Drug Formulation – The Potential of Self-Driving Labs </a></div> </div> </div> </div> </div> <div class="subnav-item flex-3"> <div class="subnav-item-content bottom-mp-fix"> <h3> Featured Resource </h3> <div class="resources flex flex-column g-5"> <a href="https://oxfordglobal.com/discovery-development/resources/sponsored/case-studies/ardigen/advancing-drug-discovery-through-innovative-technologies-strategic-collaboration"> <div class="sponsor-resource flex-column"> <div class="resource-cover img-fluid"> <div class="sponsor-resource-cover-link"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/Advancing%20Drug%20Discovery%20Mock%20Up.png" class="sponsor-resource-bubble-image"> </div> </div> <div class="resource-content p-15"> <h3 class="resource-heading"> Advancing Drug Discovery Through Innovative Technologies & Strategic Collaboration </h3> <div class="resource-abstract"> A Concise Report Featuring Insights From The Prominent Thought Leaders Of Discovery & Automate 2024 </div> </div> </div> </a> </div> </div> </div> </div> </div> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-nav-item-link">Contact</a> </li> <li class="navbar-nav-item show-sm hide-md hide-lg hide-xl"> <a href="#" class="navbar-nav-item-link">Our Brands <i class="fa-solid fa-chevron-down"></i></a> <div class="navbar-subnav"> <div class="subnav-items"> <h2> Explore our brands </h2> <div class="desc"> Our brands bring together the industry's most influential leaders and scientific experts, inspiring thought-provoking and insightful content that offers a unique perspective on R&D trends and challenges. </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/">Oxford Global</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/precision-medicine">Precision Medicine</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/discovery-development">Discovery & Development</a> </div> </div> <div class="subnav-item"> <div class="subnav-item-content"> <a href="/nextgen-biomed">NextGen Biomed</a> </div> </div> </div> </div> </li> </ul> </div> <div class="flex flex-align-center hide-sm show-md show-lg show-xl"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});" class="navbar-button">Contact</a> </div> </div> </header></div> <main id="main-content"> <div class="resource-single"> <div class="header bg-primary-light"> <div class="container-wrapper"> <div class="wide-container header-container"> <div class="header-content flex-1"> <div class="heading-smallcaps"> Target Discovery | Industry Spotlights & Insight Articles </div> <h1 class="heading"> Drugging KRAS: a Once ‘Undruggable’ Target </h1> <div class="byline"> 10 February 2022 </div> <div class="abstract"> RAS mutations are the most common subfamily of oncogenes, so finding inhibitors could be extremely valuable to oncology research. However, they also make for particularly difficult targets. Andreas Mantoulidis explains how BI have been attempting to ‘drug the undruggable.’ </div> </div> <div class="header-graphic flex-1"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/6GJ8.png" class="header-graphic-image"> </div> </div> </div> </div> <div class="container-wrapper"> <div class="wide-container"> <div class="content"> <div class="content-body text-gap"> <p></p> <p>Edited by <strong>Tom Cohen</strong></p> <p>In 2020 there were over 19 million new cancer cases, accounting for about ten million deaths. 20% to 30% of all human tumours present mutations in the RAS subfamily of oncogenes. But according to Andreas Mantoulidis, Medicinal Chemistry Research Laboratory Head at Boehringer Ingelheim, they “have remained to be an elusive therapeutic target for over 40 years.”</p> <ul> <li><a href="https://www.oxfordglobal.co.uk/resources/using-innovative-approaches-to-expand-the-druggable-genome/" target="_blank" rel="noopener">Using Innovative Approaches to Expand the Druggable Genome</a></li> <li><a href="https://www.oxfordglobal.co.uk/resources/target-identification-phenotypic-and-cell-based-screening/" target="_blank" rel="noopener">Target Identification, Phenotypic and Cell-based Screening</a></li> <li><a href="https://www.oxfordglobal.co.uk/resources/target-identification-navigating-the-intricate-environment-of-human-biology/" target="_blank" rel="noopener">Target Identification: Navigating the Intricate Environment of Human Biology</a></li> </ul> <p> </p> <p></p> <p></p> <p>For example, K-RAS has been decidedly ‘undruggable’ after decades of searching due to the lack of bindable pockets in RAS proteins for small inhibitory molecules. However, as Mantoulidis explained, the possibility of drugging RAS proteins has had a renaissance. May 2021 saw FDA approval of Sotorasib, the first K-RAS inhibitor to do so, and since then others have achieved IND and clinical approval.</p> <p></p> <p></p> <h2>Boehringer Ingelheim’s Approach to Drugging K-RAS</h2> <p></p> <p></p> <p>Boehringer Ingelheim’s journey into tackling this target started ten years ago, collaborating with Vanderbilt University. All of their K-RAS hit finding was based on nuclear magnetic resonance (NMR) fragment screening, with programs including inhibitors for KRAS<sup>G12C</sup>(off), KRAS<sup>G12D</sup>(off), pan-KRAS (off), and pan-RAS (on).</p> <p></p> <p></p> <p>Mantoulidis then answered why they would target mutant-selective K-RAS rather than casting a broader net with a pan-K-RAS inhibiting compound. “The reason is that we don’t know yet whether the pan-K-RAS approach will be tolerated in the clinic.” Furthermore, even when targeting only the G12C indication, this covers 13% of K-RAS cancers, which is still a significant figure.</p> <p></p> <p></p> <p>Therefore, Mantoulidis’s team went with a fragment-based approach, targeting G12Ci in the switch II pocket. This is contrasting with the warhead-first approach employed by competitors; those approaches start with the warhead before digging deeper into the pocket to identify clinical candidates. The team at Boehringer Ingelheim instead try to find the best K-RAS binding motif with an MNR-based fragment screen, before developing and optimising the fragment further. Then finally, they find the optimal exit vector to address the G12C position with the covalent warhead function.</p> <p></p>  <h2>Fragment Based Approach Towards K-RAS Inhibition: BI-2852 in the Switch I/II Pocket</h2>   <p>“KRAS is a switch, cycling between the on and the off state,” said Mantoulidis. “In a normal cell line, KRAS is off – resting and doing nothing.” He explained that as soon as a mutation occurs in KRAS, the tumour is in an active GTP-loaded form and signals downstream to induce cell growth and division. When KRAS is in its “on-state,” it presents a shallow lipophilic pocket called “switch I/II”. According to Mantoulidis, this pocket is very difficult to address with therapeutics to date: “it’s one of the hardest to target pockets that I’ve seen in my career so far.”</p>   <p>Mantoulidis explained that if you can address switch I/II with an inhibitor, the outcome should have acceptable selectivity and tolerability towards KRAS. After unsuccessful screening attempts of up to 1.7 million compounds, Boehringer Ingelheim switched to a fragment-first approach to address on-state KRAS.</p>   <p>NMR-based screening was employed and supplemented with X-ray confirmation of the binding site. The team did find some hits using this approach, but as Mantoulidis pointed out, the binding was very weak, and they were not able to measure the K<sub>D</sub>. What they were able to work out from the results was that each of the hits they found all had a common feature: an indole or indole-like fragment.</p>   <h2>Hit Optimisation and SAR by Catalog</h2>   <p>Mantoulidis’s team used this indole fragment as a starting point for their hit optimisation. “The next step was quite easy,” said Mantoulidis, “as we did not need to synthesise anything. We could just check the binding from the X-ray which we get quite early in the project.” Then they could ask: where in the fragment might they need to address in order to boost the potency further?</p>   <p>Mantoulidis pointed out the amino acid Asp54 on his slide and explained that the team thought they could address this part of the pocket with a salt in order to boost the potency into an acceptable range. This led them to use a SAR by catalog approach to test this hypothesis. This turned out to be successful as they ended up with new fragments with a measurable K<sub>D</sub>, although it was not potent enough to show up in biophysical assays and therefore the NMR approach was still required.</p>   <div class="wp-block-image"><figure class="aligncenter size-full is-resized"><img src="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=378&height=367&name=Picture1.png" alt="" class="wp-image-31903" width="378" height="367" srcset="https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=189&height=184&name=Picture1.png 189w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=378&height=367&name=Picture1.png 378w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=567&height=551&name=Picture1.png 567w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=756&height=734&name=Picture1.png 756w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=945&height=918&name=Picture1.png 945w, https://oxfordglobal.com/hs-fs/hubfs/Website/Images/Resources/Discovery/Picture1.png?width=1134&height=1101&name=Picture1.png 1134w" sizes="(max-width: 378px) 100vw, 378px"><figcaption><strong>Figure 1</strong> – From Mantoulidis’s slide: molecular interaction between compound and Asp54 in KRAS pocket</figcaption></figure></div>   <p>The team then continued to grow and develop their compound, improving its binding by establishing interactions with the KRAS pocket. They managed to get the molecule’s potency high enough to start measuring its affinity using biochemical assays.</p>   <p>They continued to grow the compound, optimising the binding, and trying to boost the potency. Mantoulidis’s team were unable to achieve a good enough selectivity between RAS isoforms which he described as “disappointing.” As a result, their investigations eventually led to a point where they thought they needed to stop the program or start from scratch.</p>   <h2 id="h-turning-to-open-access-collaborative-research-with-opnme">Turning to Open Access Collaborative Research with opnMe</h2>   <p>Because so much work had already been invested into the program, Boehringer Ingelheim decided to open up the molecule to research from third parties. They shared their compound, BI-2852 (along with its negative control compound, BI-2853), for free to the community on opnMe – a platform which offers compounds for free to the community in the interest of aiding research. opnMe shares well-characterised preclinical tool compounds openly so that researchers can order the compound and conduct experiments.</p>   <p>Making the molecule publicly available made sense to the company as KRAS is such a prevalent target, the more accessible research there is toward inhibiting it the better. The goal is to fulfil the potential of new small molecules through the power of collaboration. Hopefully, the full potential of these compounds will bring researchers one step closer to inhibiting cancers.</p>   <p><em>Join and network with over 200 industry leaders at <a href="https://oxfordglobal.com/discovery-us/" target="_blank" rel="noreferrer noopener">Discovery US: In-Person</a>, where we will address the latest advancements in target identification, validation and HIT optimisation.</em></p>  <div class="content-body-footer"> </div> </div> <div class="content-sidebar"> <div class="related-articles"> <h3 class="center">Related Resources</h3> <div class="article"> <a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery%20and%20Development/The%20Application%20of%20RNAi%20Therapeutics%20for%20Cardiovascular%20Disease%20Treatment.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment"> <h4> The Application of RNAi Therapeutics for Cardiovascular Disease Treatment </h4> <div class="abstract"> Alnylam Pharmaceuticals explores the possibility of treating cardiovascular disease with RNAi therapeutics. </div> <div class="read-more"> <a href="/discovery-development/resources/the-application-of-rnai-therapeutics-for-cardiovascular-disease-treatment" class="read-more-link">Read More</a> </div></a> </div> </div> <div class="article"> <a href="/discovery-development/resources/the-power-of-philanthropy-in-transforming-pancreatic-cancer-research"> <div class="cover-graphic"> <img src="https://oxfordglobal.com/hubfs/Website/Images/Resources/Discovery/The%20Role%20of%20Philanthropy%20in%20Pushing%20for%20Cancer%20Discoveries%20.png" class="cover-graphic-image"> </div> </a><div class="content"><a href="/discovery-development/resources/the-power-of-philanthropy-in-transforming-pancreatic-cancer-research"> <h4> The Power of Philanthropy in Transforming Pancreatic Cancer Research </h4> <div class="abstract"> The Stephenson Prize for innovation in pancreatic cancer research was launched alongside a $150 million gift to City of Hope. </div> <div class="read-more"> <a href="/discovery-development/resources/the-power-of-philanthropy-in-transforming-pancreatic-cancer-research" class="read-more-link">Read More</a> </div></a> </div> </div> </div> </div> </div> </div> </div> </div> <div class="newsletter-cta"> <h2 class="heading">Subscribe to our newsletter</h2> <div class="message"> Sign up for our monthly Newsletter to keep up with all things Discovery & Development </div> <div class="button-wrapper"> <a href="#" class="button hs-cta-trigger-button hs-cta-trigger-button-177049184347">Newsletter Sign-Up</a> </div> </div> </main> <div data-global-resource-path="git/og-stage/templates/partials/footer.html"><footer class="website-footer flex flex-column g-20"> <div class="footer-columns"> <div class="footer-column"> <a href="https://oxfordglobal.com" class="site-logo-link"> <img src="https://oxfordglobal.com/wp-content/uploads/2023/03/Oxford-Global-Logo-Stacked-Websize.png" class="site-logo"> </a> </div> <div class="footer-column"> <h3>Brands</h3> <ul> <li> <a href="/precision-medicine/">Precision Medicine</a> </li> <li> <a href="/discovery-development/">Discovery & Development</a> </li> <li> <a href="/nextgen-biomed/">NextGen Biomed</a> </li> </ul> </div> <div class="footer-column"> <h3>Services</h3> <ul> <li> <a href="https://oxfordglobal.com/in-person-services/"> In-Person Services </a> </li> <li> <a href="https://oxfordglobal.com/digital-marketing-services/"> Digital Marketing Services </a> </li> </ul> <h3>Upcoming Events</h3> <ul> <li> <a href="https://oxfordglobal.com/calendar/"> Event Calendar </a> </li> </ul> </div> <div class="footer-column"> <h3>Company</h3> <ul> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/about-us/"> About </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/vacancies/"> Vacancies </a> </li> <li class="elementor-icon-list-item"> <a href="https://oxfordglobal.com/csr-policy/"> CSR Policy </a> </li> <li class="elementor-icon-list-item"> <a href="javascript:postMessage({type:'HS_DISPLAY_CALL_TO_ACTION',id:130207947529});"> Contact </a> </li> </ul> </div> <div class="footer-column"> <p> <a href="tel:+441865248455">+44 1865 248 455</a><br> <a href="mailto:help@oxfordglobal.com">help@oxfordglobal.com</a> </p> <p> <strong>Our UK Address:</strong><br> Godstow Court<br> Minns Business Park<br> Botley<br> Oxford, OX2 0JB </p> <p> <strong>Our US Address:</strong><br> 100 Cambridge Street<br> 14th Floor<br> Boston<br> MA 02114 </p> </div> </div> <div class="footer-bottom grid g-20"> <div class="span8 span12-sm span12-md flex flex-column g-10"> <div class="copyright"> © Oxford Global Marketing Ltd. All rights reserved. </div> <ul class="legal-links flex flex-row g-30 flex-column-sm g-sm-10"> <li><a href="https://oxfordglobal.com/legal/">Terms & Conditions</a></li> <li><a href="https://oxfordglobal.com/legal/privacy-policy/">Privacy Policy</a></li> <li><a href="https://oxfordglobal.com/legal/website-terms/">Cookies</a></li> <li><a href="https://www.wishagency.co.uk/" target="_BLANK">Digital Agency Wish</a></li> </ul> </div> <div class="span4 span12-sm span12-md flex-align-end"> <ul class="social-links flex flex-row flex-justify-end flex-justify-center-sm flex-justify-center-md g-30"> <li><a href="https://www.facebook.com/OGConferences/" target="_BLANK"><i class="fa-brands fa-square-facebook"></i></a></li> <li><a href="https://www.linkedin.com/company/oxford-global/" target="_BLANK"><i class="fa-brands fa-linkedin"></i></a></li> <li><a href="https://twitter.com/OGConferences" target="_BLANK"><i class="fa-brands fa-square-x-twitter"></i></a></li> </ul> </div> </div> </footer></div> </div> <script src="/hs/hsstatic/jquery-libs/static-1.1/jquery/jquery-1.7.1.js"></script> <script>hsjQuery = window['jQuery'];</script>  <script defer src="/hs/hsstatic/content-cwv-embed/static-1.1293/embed.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/182600797781/1731148644227/git/og-stage/js/inlineSVG.min.js"></script> <script src="https://oxfordglobal.com/hs-fs/hub/8696823/hub_generated/template_assets/135724366742/1725380923802/git/og-stage/js/main.min.js"></script> <script> function getVideoId(url) { var regExp = /^.*(youtu.be\/|v\/|u\/\w\/|embed\/|watch\?v=|\&v=)([^#\&\?]*).*/; var match = url.match(regExp); if (match && match[2].length == 11) { return match[2]; } else { return false; } } function getVideoEmbed(id) { return '<iframe src="https://www.youtube.com/embed/' + id + '" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" allowfullscreen style="aspect-ratio: 16 / 9; width: 100%;"></iframe>'; } jQuery("div.content-body .wp-block-embed__wrapper:contains('youtu')").each(function() { var yt_url = $(this).html().trim(); var yt_id = getVideoId(yt_url); var yt_embed = getVideoEmbed(yt_id); $(this).html(yt_embed); }); </script>  <script type="text/javascript"> var _hsq = _hsq || []; _hsq.push(["setContentType", "standard-page"]); _hsq.push(["setCanonicalUrl", "https:\/\/oxfordglobal.com\/discovery-development\/resources\/drugging-kras-a-once-undruggable-target"]); _hsq.push(["setPageId", "hubdb-177028096592-7642658-170712574053"]); _hsq.push(["setContentMetadata", { "contentPageId": "hubdb-177028096592-7642658-170712574053", "legacyPageId": "hubdb-177028096592-7642658-170712574053", "contentFolderId": null, "contentGroupId": null, "abTestId": null, "languageVariantId": 177028096592, "languageCode": "en", }]); </script> <script type="text/javascript" id="hs-script-loader" async defer src="/hs/scriptloader/8696823.js"></script>  <script type="text/javascript"> var hsVars = { render_id: "3c6bb301-5420-48d3-a079-2141b2e3b3ab", ticks: 1732334888580, page_id: 177028096592, dynamic_page_id: "hubdb-177028096592-7642658-170712574053", content_group_id: 0, portal_id: 8696823, app_hs_base_url: "https://app.hubspot.com", cp_hs_base_url: "https://cp.hubspot.com", language: "en", analytics_page_type: "standard-page", scp_content_type: "", analytics_page_id: "hubdb-177028096592-7642658-170712574053", category_id: 1, folder_id: 0, is_hubspot_user: false } </script> <script defer src="/hs/hsstatic/HubspotToolsMenu/static-1.354/js/index.js"></script> </body></html>

CINXE.COM

Drugging KRAS: a Once ‘Undruggable’ Target